Personal Privacy

23andMe Sells Rights to Medication Developed Using its Users’ DNA

The Infinite Brief
DNA testing company 23andMe has sold the rights to a new drug that it has developed using its customers’ data.

The deal for the drug, which is being investigated as a potential treatment for inflammatory diseases, is with Spanish pharmaceutical company Almirall.

More than 80% of their customers have agreed to their data being used by the company for research and by scientists trying to understand the causes of diseases and how best to treat them.

As 23andMe’s genetic database grows – it has doubled in the last couple of years – it will become more likely to yield medically useful information.

Curated from New Scientist

Leave a Response